San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Nielsen BioSciences is raising $10,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Operating Officer, David Burney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nielsen BioSciences
Nielsen BioSciences, Inc. is a private, San Diego-based biotechnology company focused on offering medical professionals trusted and valued biological products with wide-ranging applications of cell-mediated immune responses. We are building on a solid foundation of over 40 years developing and delivering antigen-based products. Our research and development leverages heterogeneous antigenic profiles to enlist cell-mediated immunity in the evaluation, treatment, or prevention of diseases. Antigenic diversity enables us to effectively address conditions missed by narrowly targeted strategies.

To learn more about Nielsen BioSciences, visit http://nielsenbio.com/

Contact:
David Burney, President and Chief Operating Officer
858-571-2726
david@nielsenbio.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved